β-blockers for infantile hemangiomas: A single-institution experience

Julie Blatt, Dean S. Morrell, Scott Buck, Carlton Zdanski, Stuart Gold, Joseph Stavas, Cynthia Powell, Craig N. Burkhart

Research output: Contribution to journalArticle

39 Scopus citations

Abstract

Propranolol has become first-line therapy for the treatment of infantile hemangiomas in many centers. Of 302 children with hemangiomas seen at the University of North Carolina from 2008 through 2010, 15.6% were treated with oral propranolol alone, 5.6% with topical timolol (a propranolol derivative) alone, and 2.3% with both. The use of these agents increased over time from 7% of patients seen in 2008 to 54% of patients first seen in 2010. Starting doses of propranolol ranged from 0.25 to 1 mg/kg/d, with target doses of 1 to 4 mg/kg/d. Serious side effects, noted in 6/54 (10.9%) patients, included somnolence, bradycardia, hypotension, hypoglycemia, and mottling of extremities.The authors confirm the variation in use of propranolol for vascular lesions and extend experience with timolol. They suggest daily home monitoring of patients for the first 2 weeks of initiating or increasing doses. Frequent feeding of infants and young children on this drug is recommended.

Original languageEnglish
Pages (from-to)757-763
Number of pages7
JournalClinical Pediatrics
Volume50
Issue number8
DOIs
StatePublished - Aug 2011
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Pediatrics, Perinatology, and Child Health

Fingerprint Dive into the research topics of 'β-blockers for infantile hemangiomas: A single-institution experience'. Together they form a unique fingerprint.

  • Cite this

    Blatt, J., Morrell, D. S., Buck, S., Zdanski, C., Gold, S., Stavas, J., Powell, C., & Burkhart, C. N. (2011). β-blockers for infantile hemangiomas: A single-institution experience. Clinical Pediatrics, 50(8), 757-763. https://doi.org/10.1177/0009922811405517